Electric field therapy combined with chemo shows promise for tough pancreatic cancer
NCT ID NCT06390059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatment. The goal was to see if the combination is safe and can control the disease. Participants wore the device at home for at least 18 hours a day. The study is now complete, and results will show how well the treatment worked at stopping tumor growth and improving survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tumor Treating Fields (TTFields) device plus atezolizumab, gemcitabine, and nab-paclitaxel
What this could lead to
If successful, this combination could offer a new first-line treatment option to help control metastatic pancreatic cancer and potentially extend survival.
What could go wrong
This is a small, single-arm pilot study without a comparison group, so results may not be definitive. The treatment involves multiple drugs and a wearable device, which may cause side effects or be difficult to tolerate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Hospital Altona
Hamburg, 22763, Germany
-
Clara Campal Comprehensive Cancer Center (CIOCC)
Madrid, 28050, Spain
-
Fribourg Cantonal Hospital, Internal Medicine and Oncology
Fribourg, 1708, Switzerland
-
Inselspital, University Hospital Bern
Bern, 3010, Switzerland
-
Regional University Hospital of Malaga
Málaga, 29010, Spain
-
University Clinic of Navarra - Pamplona
Pamplona, 31008, Spain
-
University General Hospital Gregorio Maranon
Madrid, 28007, Spain
-
University Hospital Bulovka
Prague, 180 81, Czechia
-
University Hospital Foundation Jimenez Diaz
Madrid, 28040, Spain
-
University Hospital Hradec Kralove
Hradec Králové, 500 05, Czechia
-
University Hospital Motol
Prague, 150 06, Czechia
-
University Hospital Olomouc
Olomouc, 779 00, Czechia
-
University Hospital Tuebingen
Tübingen, 72076, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
University Hospital Vall d'Hebron
Barcelona, 08035, Spain